All In Biotech

Drug Trial Radar · NCT05919264

FOG-001 in Locally Advanced or Metastatic Solid Tumors

A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

619

Planned (sponsor's estimate)

Start

May 23, 2023

Primary completion

Apr 1, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Parabilis Medicines, Inc.Industry
Sponsor type
Industry
First posted
Jun 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

Conditions

  • Cancer
  • Colorectal Cancer
  • Solid Tumor
  • Locally Advanced Solid Tumor
  • Metastatic Cancer
  • WNT Pathway
  • HCC
  • Desmoid
  • Microsatellite Stable Colorectal Cancer
  • Metastatic Castration-resistant Prostate Cancer
  • Familial Adenomatous Polyposis (FAP)
  • Endometrial Carcinoma
  • Prostate Cancer
  • Microsatellite Instability-High Colorectal Cancer
  • Adamantinomatous Craniopharyngioma

Interventions

  • FOG-001Drug

    FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days

  • mFOLFOX-6Drug

    mFOLFOX-6 will be administered per the prescribing information in combination with FOG-001

  • NivolumabDrug

    Nivolumab will be administered per the prescribing information in combination with FOG-001

  • Trifluridine/tipiracilDrug

    Trifluridine/tipiracil will be administered per the prescribing information in combination with FOG-001

  • BevacizumabDrug

    Bevacizumab will be administered per the prescribing information in combination with FOG-001

  • FOG-001Drug

    FOG-001 will be administered subcutaneous at assigned doses in continuous cycles of 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. During dose escalation and dose expansion measure incidence and severity of treatment emergent adverse events by CTCAE v5.0Time frame: Through study completion, an average of 10 months
  2. During dose escalation characterize dose-limiting toxicities (DLTs)Time frame: 1 treatment cycle (28 days)
  3. During dose expansion describe the Overall Response Rate using RECIST v1.1Time frame: Every 63 days until study completion, approximately 10 months on average
  4. During dose expansion describe the Disease Control Rate using RECIST v1.1 (Part 2a only)Time frame: 4 months
  5. During dose expansion describe the PSA30 response rate for participants with prostate cancerTime frame: Baseline, weekly during the first 2 cycles (56 days), bi-weekly during the Cycle 3 (28 days), and then monthly (up to approximately 7 months)

Locations

33 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona · Recruiting

  • Honor Health

    Scottsdale, Arizona · Recruiting

  • Arizona Cancer Center at University of Arizona

    Tucson, Arizona · Recruiting

  • University of California, Los Angeles (UCLA)

    Los Angeles, California · Recruiting

  • Stanford Cancer Institute, Stanford University

    Palo Alto, California · Recruiting

  • University of California San Francisco, Helen Diller Family Comprehensive Cancer Center

    San Francisco, California · Recruiting

  • Sarcoma Oncology Center

    Santa Monica, California · Recruiting

  • University of Colorado

    Aurora, Colorado · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • Johns Hopkins University, Sibley Memorial Hospital

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • Florida Cancer Specialists

    Lake Mary, Florida · Terminated

  • Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • M Health Fairview University of Minnesota Medical Center

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • University Hospitals Cleveland Medical Center, Seidman Cancer Center

    Cleveland, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • University of Pennsylvania, Perelman School of Medicine

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center, Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • South Texas Accelerated Research Therapeutics, LLC

    San Antonio, Texas · Recruiting

  • University of Virginia

    Charlottesville, Virginia · Recruiting

  • University of Wisconsin, Carbone Cancer Center

    Madison, Wisconsin · Recruiting

  • Integrated Clinical Oncology Network (ICON)

    South Brisbane, Queensland, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.